|Mr. Michael K. McGarrity||CEO & Exec. Director||474.13k||N/A||1963|
|Mr. Ron Kalfus||Chief Financial Officer||N/A||N/A||1974|
|Mr. Joseph Sollee||Exec. VP of Corp. Devel. & Gen. Counsel||N/A||N/A||1965|
|Mr. John A. Bellano||Chief Commercial Officer||N/A||N/A||1969|
|Ms. Miriam Reyes||Exec. VP of Operations||N/A||N/A||1973|
|Dr. Wim Van Criekinge||Chief Scientific Officer||N/A||N/A||1972|
|Mr. Paul Marr||Exec. VP of Sales for North America||N/A||N/A||N/A|
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA’s ISS Governance QualityScore as of January 28, 2023 is 5. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 1; Compensation: 10.